Patient Education Guide
Wegovy Pill Results: What Weight Loss Can You Expect?
The Evidence-Based Answer: In the OASIS-4 clinical trial — the key Phase 3 trial for the Wegovy Pill in weight management — adults taking oral semaglutide lost an average of 16.6% of their body weight over 68 weeks. Earlier OASIS 1 trial data at a comparable dose showed up to 15.1% average weight loss. In practice, results vary: some patients lose significantly more, others less. The key factors are consistency with the Sip & Go routine, dose escalation compliance, diet, physical activity, and individual response to the medication.16.6%Average weight loss — OASIS-4 (68 weeks)
15.1%Average weight loss — OASIS 1 (64 weeks)
78%of patients lost ≥5% body weight (OASIS-4)
Clinical Evidence
1. What the Clinical Trials Show
The Wegovy Pill has been studied in large-scale, randomised, placebo-controlled Phase 3 clinical trials — the gold standard of medical evidence. The two most important for understanding weight loss results are the OASIS 1 and OASIS-4 trials, both conducted by Novo Nordisk and published in peer-reviewed journals.
OASIS 1 Trial
The OASIS 1 trial studied oral semaglutide 50mg once daily (an earlier formulation comparable to the licensed 25mg maintenance dose) in 667 adults with obesity or overweight with a weight-related condition, over 68 weeks. Participants also received a reduced-calorie diet and exercise guidance — reflecting real-world treatment conditions.
The results were clinically significant. Patients on oral semaglutide lost an average of 15.1% of their body weight, compared to 2.4% in the placebo group. More than half of participants lost at least 15% of their body weight, and around a third lost 20% or more — results that overlap with the outcomes seen from the standard Wegovy 2.4mg injection in the STEP 1 trial.
OASIS-4 Trial
The OASIS-4 trial is the pivotal registration trial for the licensed Wegovy Pill formulation. It studied the 25mg maintenance dose in a broader adult population over 68 weeks and reported average weight loss of 16.6% — a clinically meaningful result comparable to the standard Wegovy injection and representative of real-world outcomes for the licensed product.
Both trials also demonstrated meaningful improvements in secondary health markers — including blood pressure, blood sugar levels, cholesterol, and waist circumference — reinforcing that the Wegovy Pill delivers genuine cardiometabolic benefit beyond weight loss alone.
| OASIS 1 outcome | Oral semaglutide | Placebo |
|---|---|---|
| Average weight loss at 68 weeks | 15.1% | 2.4% |
| Lost ≥5% of body weight | 85% | 26% |
| Lost ≥10% of body weight | 69% | 12% |
| Lost ≥15% of body weight | 52% | 6% |
| Lost ≥20% of body weight | 34% | 3% |
| Reduction in waist circumference | −13.4 cm | −3.2 cm |
ℹ️ Why the two figures differ slightly
OASIS 1 used a 50mg daily dose in a more tightly controlled trial population; OASIS-4 reflects the licensed 25mg formulation in a broader real-world population. The 16.6% figure from OASIS-4 is the more clinically representative benchmark for patients starting the Wegovy Pill today.
Your Journey
2. Month-by-Month: What to Expect on Your Journey
Weight loss on the Wegovy Pill follows a characteristic pattern — gradual in the early weeks, accelerating as the dose increases, and stabilising at a new lower set point once the maintenance dose is reached. Understanding this timeline helps patients stay motivated and avoid the frustration of comparing early results to the final outcome.
Weeks 1–4
1.5 mg
Appetite begins to reduce. Nausea most likely in this phase. Early weight loss of 1–3 kg typical.
Weeks 5–8
4 mg
Appetite suppression strengthens. Food noise noticeably quieter. Side effects usually easing.
Weeks 9–12
9 mg
Weight loss accelerating. Many patients notice clothes fitting differently. Energy levels improving.
Week 13+
25 mg
Maintenance dose reached. Full treatment effect builds over the following weeks and months.
| Timeframe | Typical milestone | What's happening |
|---|---|---|
| Weeks 1–4 (1.5 mg) | 1–3 kg weight loss; reduced appetite | Semaglutide begins activating GLP-1 receptors; food noise starts to quieten; nausea is most common at this stage |
| Weeks 5–8 (4 mg) | 3–6 kg weight loss; side effects easing | Dose increase amplifies appetite suppression; most patients find nausea has significantly improved |
| Weeks 9–12 (9 mg) | 5–9 kg cumulative weight loss | Substantial reduction in hunger between meals; many patients naturally eating smaller portions without effort |
| Months 4–6 (25 mg) | 8–12 kg cumulative weight loss | Maintenance dose reached; full effect building; meaningful changes in body composition becoming visible |
| Months 6–12 (25 mg) | 10–17 kg cumulative weight loss | Steady progress continues; weight loss may plateau briefly before resuming; lifestyle habits consolidating |
| Months 12–17 (25 mg) | 13–20+ kg cumulative weight loss | OASIS-4 average (14%) and OASIS 1 average (15.1%) achieved around this point for most patients |
⚠️ Plateaus Are Normal — and Temporary
Most patients experience at least one period where weight loss slows or pauses, typically around months 3–4 as the body adjusts to a new set point. This is a normal physiological response, not a sign that the treatment has stopped working. Maintaining consistency with the Sip & Go routine and continuing lifestyle habits through a plateau is key — weight loss typically resumes.
Illustrative Examples
3. Illustrative Results at Different Starting Weights
To make the trial averages meaningful, the examples below show illustrative weight loss for patients at different starting weights, based on the OASIS-4 trial average of 13.6% body weight reduction over 68 weeks. These are illustrative figures for educational purposes — individual results will vary.
Patient A — Starting Weight: 90 kg
−12.2 kg
Approx. 13.6% of 90 kg lost · Weight at 68 weeks: approx. 77.8 kg · Equivalent to losing over 1.9 stone
Patient B — Starting Weight: 110 kg
−15.0 kg
Approx. 13.6% of 110 kg lost · Weight at 68 weeks: approx. 95 kg · Equivalent to losing over 2.3 stone
Patient C — Starting Weight: 130 kg
−17.7 kg
Approx. 13.6% of 130 kg lost · Weight at 68 weeks: approx. 112.3 kg · Equivalent to losing nearly 2.8 stone
ℹ️ These Are Illustrative Averages — Not Guarantees
Clinical trial averages mask a wide range of individual results. In the OASIS-4 trial, some patients lost significantly more than 13.6% and others less. The illustrative examples above are based on the trial average only. Your prescriber can give you a personalised picture of what to expect based on your individual health history, starting weight, and lifestyle.
Wider Health Benefits
4. Beyond the Scales: Other Health Benefits
The Wegovy Pill's benefits extend well beyond weight loss. In the OASIS trials, participants also experienced meaningful improvements across a range of important health markers — findings that reinforce the clinical value of treatment even for patients whose weight loss is below the trial average.
A 13.6% reduction in body weight is associated with clinically meaningful improvements in blood pressure, blood sugar regulation, joint load, sleep quality, and cardiovascular risk. For many patients, these secondary benefits are as important — if not more important — than the number on the scales.
| Health marker | Improvement seen in OASIS trials |
|---|---|
| Waist circumference | Average reduction of 13.4 cm (OASIS 1) |
| Systolic blood pressure | Meaningful reduction vs placebo |
| HbA1c (blood sugar) | Significant improvement in patients with pre-diabetes or type 2 diabetes |
| Cholesterol (LDL) | Reduction in LDL ('bad') cholesterol |
| Physical functioning | Significant improvement in patient-reported ability to move and carry out daily activities |
| Quality of life | Meaningful improvement in validated quality of life scores |
What Influences Outcomes
5. Factors That Affect Your Results
No two patients respond identically to the Wegovy Pill. A number of factors influence how much weight you lose and how quickly — some within your control, others less so.
| Factor | Impact on results | What you can do |
|---|---|---|
| Sip & Go compliance | High — absorption varies significantly if the routine is not followed precisely | Take the tablet the same way every morning: empty stomach, up to 120ml plain water, 30-minute wait |
| Diet | High — the pill reduces appetite but does not make poor food choices calorie-neutral | Prioritise protein, vegetables, and fibre; avoid high-calorie processed foods that bypass the satiety signal |
| Physical activity | Moderate to high — exercise accelerates fat loss and protects muscle during calorie restriction | Aim for at least 150 minutes of moderate activity per week as per NHS guidelines |
| Starting weight | Moderate — patients with higher starting weights tend to lose more in absolute terms | This is fixed — focus on the percentage outcome, not absolute kg |
| Dose escalation compliance | High — rushing to a higher dose or skipping steps reduces tolerability and may force dose reductions | Follow the escalation schedule: 1.5 mg → 4 mg → 9 mg → 25 mg, one step per month as tolerated |
| Individual biology | Moderate — genetic factors, gut microbiome, hormonal status, and metabolic rate all play a role | Discuss with your prescriber if results are significantly below expectations after 12 weeks at the maintenance dose |
| Consistency of treatment | Very high — missed doses reduce the drug's steady-state effect and can slow or stall progress | Build the Sip & Go routine into a daily habit — same time, same place, every morning |
Comparing Outcomes
6. How the Wegovy Pill Compares on Results
Patients often ask how the pill's results stack up against other available weight loss treatments. The table below provides a like-for-like comparison using published clinical trial data.
The Wegovy Pill sits firmly in the top tier of available weight loss treatments — delivering results significantly greater than older medicines or lifestyle intervention alone, and broadly comparable to the standard injectable semaglutide dose. For patients who want to avoid injections, it represents a genuine step change from previous oral options.
| Treatment | Average weight loss | Trial | Duration |
|---|---|---|---|
| Wegovy Pill (25 mg daily) | 14–17% | OASIS-4 / OASIS 1 | 68 weeks |
| Wegovy Injection (2.4 mg weekly) | ~15% | STEP 1 | 68 weeks |
| Wegovy Injection (7.2 mg weekly) | ~20.7% | STEP UP | 72 weeks |
| Mounjaro (15 mg weekly) | ~22.5% | SURMOUNT-1 | 72 weeks |
| Orlistat (oral, NHS) | ~3–5% | Multiple RCTs | 12 months |
| Lifestyle intervention alone | ~3–5% | NHS/NICE benchmarks | 12 months |
Common Questions
Frequently Asked Questions
Based on the OASIS-4 trial, the average weight loss is 13.6% of starting body weight over 68 weeks. The OASIS 1 trial showed up to 15.1% average weight loss at a comparable dose. Individual results vary — some patients lose significantly more, others less. Your prescriber can help you set realistic, personalised expectations.
Most patients notice a reduction in appetite within the first one to two weeks of starting at the 1.5mg dose. Early weight loss of 1–3kg is typical in the first month. The full treatment effect builds progressively as the dose is increased, with the strongest results seen from Month 4 onwards at the 25mg maintenance dose.
If you are not seeing expected results after 12–16 weeks at the maintenance dose, discuss this with your prescriber. Common reasons include inconsistency with the Sip & Go routine (which reduces absorption), diet patterns that counteract the appetite suppression, insufficient physical activity, or individual variation in response to semaglutide. In some cases, a different treatment may be more appropriate.
Yes — clinical trial averages include all participants, including those who lost very little. In OASIS 1, 34% of patients lost 20% or more of their body weight. Patients who combine consistent treatment with improved diet and regular exercise tend to see the strongest results.
The clinical evidence suggests that significant weight regain is likely after stopping GLP-1 treatments including semaglutide, as the appetite-regulating effects are lost. Studies indicate most patients regain a substantial proportion of lost weight within 12–20 months of stopping. Happy Pharmacy has a dedicated guide on long-term use and maintaining results after treatment.
At the standard doses, the results are broadly comparable — both produce average weight loss of around 14–17% of body weight. The higher-dose 7.2mg injection currently produces greater average weight loss (~20.7%), but for patients who cannot or prefer not to use injections, the pill delivers clinically meaningful results that represent a significant improvement on older treatment options.
Ready to Start Your Wegovy Pill Journey?
Happy Pharmacy is a GPhC-registered online pharmacy (No. 9012585). Our clinical team provides thorough assessments and ongoing support to help you achieve the best possible results on the Wegovy Pill. Trustpilot Rating: 4.8 ★
Book Your Free Consultation →
1. Oral semaglutide 50mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402(10403):705–719. | 2. Novo Nordisk. OASIS-4 trial results — oral semaglutide for weight management. Data presented at European Association for the Study of Obesity (EASO), 2025. | 3. NICE. Semaglutide for managing overweight and obesity. Technology appraisal guidance TA875. March 2023. | 4. Efficacy and Safety of Semaglutide 7.2mg in Obesity — STEP UP Trial. American Diabetes Association, 2025. | 5. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021;384:989–1002. | Happy Pharmacy (GPhC No. 9012585). The information in this guide is intended for general educational purposes only and does not replace personalised medical advice. Individual results will vary. Patient examples are illustrative only and based on published trial averages.